
Prostate Cancer
Latest News
Latest Videos

Shorts




Podcasts
CME Content
More News

Frequent hydration, salivary gland stimulation, and overnight humidifier use are strategies Bradley J. Stish, MD, employs to manage dry mouth.

Bradley J. Stish, MD, emphasized the role of decision-making processes between physicians and patients when deciding between 2.5 and 5 mg of oxybutynin.

Investigators of a prospective validation study highlighted the potential of a urine-based assay to reduce surgical biopsies deemed unnecessary.

Management strategies for oxybutynin-induced xerostomia include hydration, sugar-free gum, and humidification.

The project will be focused on increasing awareness and early detection of the disease and generate high-quality data to inform improvement of care.

Rahul Aggarwal, MD, discussed the high unmet needs of neuroendocrine prostate cancer, highlighting biopsy triggers, genomic markers, and emerging targets.

The phase 3 TALAPRO-3 study met its primary end point, showing a clinically meaningful reduction in the risk of progression or death in HRR-mutant HSPC.

Benjamin Garmezy, MD, discussed the potential of a GSPT1 molecular glue degrader and a trispecific T-cell engager in treating select prostate cancers.

For patients with more aggressive disease, the addition of chemotherapy to the ARPI/ADT backbone may optimize efficacy outcomes without comprising safety.

Emergent phase 1 LuPARP study data suggest that metastatic castration-resistant prostate cancer could be treated with PARP inhibition and radionuclides.

Twenty patients with low- to intermediate-risk localized prostate cancer underwent successful implantation with the antiandrogen-eluting implants.

Scott Tagawa, MD, MS, FACP, FASCO, evaluated how the rPFS improvement with lutetium 177 could help integrate the treatment into the frontline metastatic HSPC setting.

Oliver Sartor, MD highlighted SBRT, hormonal therapy, and the PSMA-DC regimen for patients with biochemical recurrence and PSMA-PET–positive disease.

By harnessing investigator-generated data, companion diagnostics, and biomarker-directed treatment selection, clinicians can optimize care for HSPC.

Bridget Koontz, MD, discussed evaluating the role of concurrent hormone therapy and brachytherapy for prostate cancer that she presented at ASCO GU.

Oncologists discussed key abstracts assessing AI models for treatment selection, AKT inhibition, and PARP inhibition in specific prostate cancer types.

The triplet regimen also improved health-related quality of life and pain compared with ADT plus ARPI alone in patients with metastatic hormone-sensitive prostate cancer.

CAR T-cell therapies and T-cell engagers may produce an “exciting” benefit on the radiosensitization of prostate tumors.

The phase 2 study aimed to compare the safety of pembrolizumab and radiation with or without olaparib in this high-risk population.

Data from PEACE-2 may challenge the current definition of "very high-risk" localized prostate cancer without nodal disease involvement.

Results from the PEACE-3 trial found an extended OS after patients with metastatic castration-resistant prostate cancer were treated with enzalutamide/radium-223.

Data from the CAPItello-281 trial may support capivasertib/abiraterone as a first-in-class targeted therapy in this metastatic hormone-sensitive prostate cancer population.

Data from the phase 2 BRCAAway trial showed the longest survival with olaparib plus abiraterone/prednisone vs each agent given alone or sequentially.

Discover how PSMA PET sharpens staging, guides radioligand therapy sequencing, and tackles real‑world access hurdles in advanced prostate cancer.






























































